Holen Sie sich die Stockscreener-App
73.90
4.13%
-3.01
Schlusskurs vom Vortag:
$76.91
Offen:
$76.53
24-Stunden-Volumen:
724.33K
Relative Volume:
0.48
Marktkapitalisierung:
$5.94B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-12.44
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-6.07%
1M Leistung:
+2.72%
6M Leistung:
+42.64%
1J Leistung:
+53.41%
1-Tages-Spanne:
$73.09
$76.95
1-Wochen-Bereich:
$73.03
$79.03
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
74.02 | 6.17B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Marshall Wace LLP Reduces Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stock Position Raised by Hood River Capital Management LLC - MarketBeat
Emma Reeve Sells 733 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Can PTC Therapeutics Inc. (BH3) stock sustain breakout momentumShare Buyback & Weekly Watchlist for Consistent Profits - Newser
Russell Investments Group Ltd. Buys 118,105 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
How higher bond yields impact PTC Therapeutics Inc. (BH3) stock2025 Price Action Summary & Step-by-Step Trade Execution Guides - Newser
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells $271,051.96 in Stock - MarketBeat
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? - AOL.com
Why PTC Therapeutics Inc. stock could rally in 2025Inflation Watch & Target Return Focused Picks - Newser
Will PTC Therapeutics Inc. (BH3) stock outperform global peers2025 Analyst Calls & Entry Point Strategy Guides - Newser
PTC Therapeutics (NASDAQ:PTCT) Shares Down 5.6%Time to Sell? - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Panagora Asset Management Inc. Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT): Revisiting Valuation After Strong Multi‑Year Share Price Gains - Yahoo Finance
PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs - The Globe and Mail
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - Nasdaq
PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says - marketscreener.com
Prudential Financial Inc. Has $4.12 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics stock price target raised to $55 from $50 at Goldman Sachs - Investing.com UK
Legal & General Group Plc Grows Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08 - marketscreener.com
Can PTC Therapeutics Inc. (BH3) stock retain market dominance2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
How PTC Therapeutics Inc. (BH3) stock moves on employment dataQuarterly Earnings Report & Long-Term Capital Growth Strategies - Newser
Is PTC Therapeutics Inc. stock a buy for dividend growth2025 Trading Recap & Reliable Volume Spike Trade Alerts - Newser
Why PTC Therapeutics Inc stock could rally in 2025Weekly Earnings Recap & Fast Gain Swing Trade Alerts - BỘ NỘI VỤ
Will PTC Therapeutics Inc. (BH3) stock deliver stable dividendsPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
PTC Therapeutics (PTCT): Exploring Valuation After Recent 16% Share Price Climb - Sahm
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com
PTC Therapeutics downgraded at RBC as Sephience sales priced in - MSN
PTC Therapeutics Shares Drop After RBC Downgrade - marketscreener.com
PTC Therapeutics downgraded at RBC as Sephience sales priced in (PTCT:NASDAQ) - Seeking Alpha
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - The Manila Times
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
PTC Therapeutics stock downgraded by RBC Capital as shares near fair value - Investing.com Canada
RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82 - marketscreener.com
(PTCT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Elo Mutual Pension Insurance Co Makes New $689,000 Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
How The Sephience Launch Is Reshaping The Story For PTC Therapeutics’s Valuation - Yahoo Finance
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 - The Globe and Mail
Advantage Alpha Capital Partners LP Invests $204,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Stock on November 28, 2025: S&P SmallCap 600 Debut, Insider Selling and a 90% YTD Rally - ts2.tech
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P 600 Health Care - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P Composite 1500 - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P 600 - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P 1000 - marketscreener.com
PTC Therapeutics (NASDAQ:PTCT) Insider Sells $6,001,672.32 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Allan Steven Jacobson Sells 11,801 Shares - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):